The University of Southampton
University of Southampton Institutional Repository

Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine

Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine
Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine
With the successful development of meningococcal vaccines against other serogroups, disease caused by Neisseria meningitidis serogroup B now accounts for a disproportionate frequency compared with other serogroups, particularly in the US and Europe. Infants and adolescents bear the highest incidence of disease, which typically manifests as meningitis and septicemia. This vaccine profile article examines a bivalent factor H binding protein (fHbp; also known as LP2086) vaccine that has now been approved by the US FDA for use in 10- to 25-year olds. The manufacturer has shelved plans for further investigation of its use in infants because of high rates of fever in Phase I and II trials in that age group.
fHbp, MenB vaccine, meningococcal vaccine, rLP2086, Trumenba
1476-0584
493-503
Brendish, Nathan J
27ebd617-d0f0-4d6d-a666-429fae48d795
Read, Robert C
b5caca7b-0063-438a-b703-7ecbb6fc2b51
Brendish, Nathan J
27ebd617-d0f0-4d6d-a666-429fae48d795
Read, Robert C
b5caca7b-0063-438a-b703-7ecbb6fc2b51

Brendish, Nathan J and Read, Robert C (2015) Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine. Expert Review of Vaccines, 14 (4), 493-503. (doi:10.1586/14760584.2015.1015997). (PMID: 25703792 )

Record type: Article

Abstract

With the successful development of meningococcal vaccines against other serogroups, disease caused by Neisseria meningitidis serogroup B now accounts for a disproportionate frequency compared with other serogroups, particularly in the US and Europe. Infants and adolescents bear the highest incidence of disease, which typically manifests as meningitis and septicemia. This vaccine profile article examines a bivalent factor H binding protein (fHbp; also known as LP2086) vaccine that has now been approved by the US FDA for use in 10- to 25-year olds. The manufacturer has shelved plans for further investigation of its use in infants because of high rates of fever in Phase I and II trials in that age group.

Full text not available from this repository.

More information

e-pub ahead of print date: 23 February 2015
Published date: 14 April 2015
Keywords: fHbp, MenB vaccine, meningococcal vaccine, rLP2086, Trumenba
Organisations: NIHR Southampton Respiratory Biomedical Research Unit, Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 380715
URI: https://eprints.soton.ac.uk/id/eprint/380715
ISSN: 1476-0584
PURE UUID: 8929d1a7-e64b-4555-b437-8d104a147925
ORCID for Robert C Read: ORCID iD orcid.org/0000-0002-4297-6728

Catalogue record

Date deposited: 03 Sep 2015 13:53
Last modified: 20 Jul 2019 00:42

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×